, ? Tableau 2: Taux de survenue d'hypocalcémie selon les données de la littérature, p.42

?. Tableau, Taux de survenue de réactions allergiques selon les données de la littérature, vol.3

?. Tableau, Survenue d'infections cutanées sous denosumab: données de la littérature, vol.4

?. Tableau, Taux de survenue de douleurs osseuses selon les données de la littérature, vol.5

, ? Tableau 6: Classification actuelles des Ostéochimionécroses des maxillaires, p.53

?. Tableau, Aide à l'évaluation du risque de développer une ostéochimionécrose

?. Tableau, Taux de survenue d'ostéochimionécroses selon les données de la littérature, vol.8

?. Tableau, Résumé des fréquences des effets secondaires 31, vol.9

?. Tableau, Tableau initial de relevé des données patients, vol.10

?. Tableau, Caractéristiques des patients inclus dans l'étude, vol.11

?. Tableau, Incidence cumulée des nécroses en fonction du temps, vol.12

?. Tableau, Guérisons et traitements des patients de l'étude ayant développés une nécrose, vol.13

?. Tableau, Délais en mois avant la survenue d'une nécrose, vol.14

, Co-morbidités chez les patients ayant des ostéochimionécroses, ? Tableau, vol.15, p.90

?. Tableau, Influence de facteurs sur le taux des nécroses, vol.16

B. 1. Austin, M. Yang, Y. C. Vittinghoff, E. Adami, S. Boonen et al., relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures, JBMR, pp.687-693, 2012.

M. R. Mcclung, S. Boonen, O. Törring, C. Roux, R. Rizzoli et al., Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis, JBMR, pp.211-218, 2012.

T. L. Aghaloo, A. L. Felsenfeld, and S. Tetradis, Osteonecrosis of the jaw in a patient on Denosumab, J Oral Maxillofac Surg, pp.959-63, 2010.

T. M. You, K. H. Lee, S. H. Lee, and W. Park, Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics. Oral Surg Oral Med Oral Pathol Oral Radiol, pp.2212-4403, 2015.

K. Daisuke, K. Hiroto, Y. Tsukasa, I. Shintaro, I. Takeshi et al., Denosumab for Treatment of a recurrent Cervical giant-Cell Tumor

, Asian Spine J, vol.10, issue.3, pp.553-557, 2016.

A. Ezra and G. Golomb, Administration routesand delivery systems of bisphosphonates for the treatment of bone resorption, Adv Drug Deliv Rev, vol.42, pp.175-95, 2000.

H. Fleisch, Bisphosphonates in Bone Deseas: From the laboratory to the patient, 2000.

N. Ohga, Y. Yamazaki, K. Tsuboi, and Y. Kitagawa, Healing of osteonecrosis of the jaw (ONJ) after discontinuation of denosumab in a patient with bone metastases of colorectal cancer: a case report and hypothesis, Quintessence Int, pp.621-627, 2015.

K. H. Taylor, L. S. Middlefell, and K. D. Mizen, Osteonecrosis of the jaws induced by antiRANK ligand therapy, British Journal of Oral and Maxillofacial Surgery, vol.48, pp.221-224, 2010.

J. Malan, K. Ettinger, E. Naumann, and O. R. Beirne, The relationships of denosumab pharmacology and osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol, vol.114, pp.671-676, 2012.

D. Brunengo, G. Chyderiotis, and N. Couprié, Précis de biopathologie analyses médicales spécialisées. Lyon: Biomnis, 2012.

, Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis, Conférence de consensus, pp.646-50, 1993.

I. R. Reid, S. Sharma, R. Kalluru, and C. Eagleton, Treatment of Paget's Disease of Bone with Denosumab: Case Report and Literature Review, Calcif Tissue Int, 2016.

, AdvisoryTask Force on Bisphosphonate-related Osteonecrosis of the jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on Bisphosphonate-related Osteonecrosis of the jaws, J Oral Maxillofac Surg, vol.65, issue.3, pp.369-376, 2007.

C. Errani, A. F. Mavrogenis, L. Cevolani, S. Spinelli, A. Piccioli et al., Treatment for long bone metastases based on a systematic literature review, Eur J Orthop Surg Traumatol, vol.26, pp.1-7, 2016.

M. Kundan-kisanrao-nawale, S. Vyas, A. Kane, and . Patil, Metastatic tumors in the jaw bones: A retrospective clinicopathological study of 12 cases at Tertiary Cancer Center, J Oral Maxillofac Pathol, vol.20, issue.2, pp.252-255, 2016.

A. Dufresne, O. Derbel, P. Cassier, G. Vaz, A. V. Decouvelaere et al., Giant-cell tumor of bone, anti-RANKL therapy, Bonekey Rep, vol.1, p.149, 2012.
DOI : 10.1038/bonekey.2012.149

URL : http://europepmc.org/articles/pmc3868728?pdf=render

D. Kajiwara, H. Kamoda, T. Yonemoto, S. Iwata, T. Ishii et al., Denosumab for treatment of a recurrent Cervical Giant-cell Tumor, Asian Spine J, vol.10, pp.553-557, 2016.

R. R. Goldenberg, C. J. Campbell, and M. Bonfiglio, Giant-cell tumor of bone An analysisof two hundred eighteen cases, J Bone joint Surg Am, vol.52, pp.619-64, 1970.

S. Zhang, J. Zhang, and X. Wang, Comparaison of tumor curettage and resection for treatment of giant-cell tumor of the bone around the knee joint, Pak J Med sci, vol.32, pp.662-666, 2016.

A. F. Kamal, E. L. Simlolon, Y. Prabowo, and E. U. Hutagalung, Wide resection versus curettage with adjuvant therapy for giant cell tumor of bone, Journal of orthopaedic Surgery, vol.24, pp.228-259, 2016.

C. L. Gaston, R. J. Grimer, M. Parry, S. Stacchiotti, P. Dei-tos et al., Current status and unanswered questions on the use of Denosumab in giant-cell tumor of bone, Clin sarcoma Res, pp.6-15, 2016.

S. Chawla, R. Henshaw, and L. Seeger, Safety and effcacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study, Lancet Oncol, vol.14, pp.901-909, 2013.

R. Bartsch, G. G. Steger, M. Gnant, and R. Ziebermayr, Breast Cancer: Rank Ligand Inhibition. Breast Care, vol.5, pp.320-325, 2010.
DOI : 10.1159/000321122

URL : http://europepmc.org/articles/pmc3132956?pdf=render

H. Hsu, D. L. Lacey, C. R. Dunstan, I. Solovyev, A. Colombero et al., Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand, Proc Natl Acad Sci, vol.96, pp.3540-3545, 1999.
DOI : 10.1073/pnas.96.7.3540

URL : http://www.pnas.org/content/96/7/3540.full.pdf

D. Cappelen, N. H. Luong-nguyen, S. Bongiovanni, O. Grenet, C. Wanke et al., Transcriptional program of mouse osteoclast differentiation governed by the macrophage colony-stimulating factor and ligand for the receptor activator of NFkappa B, J Biol Chem, vol.277, pp.21971-82, 2002.

A. Stopeck, A. Lipton, J. J. Body, G. G. Steger, K. Tonkin et al.,

, Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study, J Clin Oncol, pp.10-28, 2010.

K. Fizazi, Denosumab versus zoledronic acid for treatment of bone metastases in men with castration resistant prostate cancer: a randomised, double-blind study, Etude pivotal 20050103 retenue lors de l'évaluation de l'AMM, vol.377, pp.813-835, 2011.

A. Lipton, Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials, Eur J Cancer, pp.3082-92, 2012.

A. Kyrgidis and K. Toulis, Safety and efficacy of denosumab in giant-cell tumour of bone, Lancet Oncol, pp.513-517, 2010.

E. Shane, D. Burr, and P. R. Ebeling, Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research, J Bone Miner Res, vol.25, pp.2267-94, 2010.

S. Subramanian and M. J. Parker, Atypical femur fractures-Patient characteristics and results of intramedullary nailing for a series of 21 patients, Acta Orthop Belg, 2016.

C. Errani, A. F. Mavrogenis, L. Cevolani, S. Spinelli, A. Piccioli et al., Treatment for long bone metastases based on a systematic literature review, Eur J Orthop Surg Traumatol. 2016 Sept, pp.1-7

R. A. Adler, Bisphosphonates and atypical femoral fractures, Curr Opin Endocrinol Diabetes Obes, vol.23, issue.6, pp.430-436, 2016.

S. Khosla, D. Burr, and J. Cauley, Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the

, J Bone Miner Res, vol.22, pp.1479-1491, 2007.

S. L. Ruggiero, T. B. Dodson, and L. A. Assael, American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2009 update, Aust Endod J, vol.35, pp.119-130, 2009.

S. L. Ruggiero, T. B. Dodson, and J. Fantasia, American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update, Aust Endod J, vol.72, pp.1938-1956, 2014.

A. Furtado, I. , F. Caldas, C. Lança, F. Salvado et al., Anatomic factors related to bisphosphonat osteonecrosis of the jaws: a portuguese retrospective study, Acta med Port, vol.25, issue.2, pp.106-110, 2012.

A. Barmias, . Kastritisc, L. A. Moulopoulos, I. Melakopoulos, G. Bozas et al., Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors, J Clin Oncol, vol.23, issue.34, pp.8580-8587, 2005.

A. O. Hoff, B. B. Toth, K. Altundag, M. M. Johnson, C. L. Warneke et al., Frequency and risk factors associeted with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates, J Bone Miner Res, vol.23, issue.6, pp.826-836, 2008.

P. Diz, J. L. Lopez-cedrun, J. Arenaz, and C. Scully, Denosumab-related osteonecrosis of the jaw, J Am Dent Assoc, vol.143, pp.981-984, 2012.

S. Otto, S. Baumann, M. Ehrenfeld, and C. Pautke, Successful surgical management of osteonecrosis of the jaw due to RANK-Ligand inhibitor treatment using fluorescence guided bone resection, J Craniomaxillofac Surg, vol.41, pp.694-698, 2014.

O. 'halloran, M. Boyd, N. M. Smith, and A. , Denosumab and osteonecrosis of the jaws-the pharmacology, pathogenesis and a report of two cases, Aust Dent J. Dec, 2014.

A. Barnias, E. Kastrinis, and C. Bamia, Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors, J Clin Oncol, vol.23, pp.8580-8587, 2005.

B. Guillaume and D. Chappart, Ostéonécrose de la machoire et chirurgie implantaire. Rapport et prévention thérapeutique, Le chirurgien dentiste de France, vol.78, pp.45-52, 2008.

G. Lodi, A. Sardella, A. Salis, F. Demarosi, M. Tarozzi et al., Tooth extraction in patients taking intravenous bisphosphonates: a preventive protocol and case series

, J Oral Maxillofac Surg, vol.68, pp.107-117, 2010.

M. Mozzati, V. Arata, and G. Gallesio, Tooth extraction in patients on zoledronic acid therapy, Oral Oncology, vol.48, pp.817-821, 2012.

, AFSSAPS: Recommandations: Prescription des antibiotiques en pratique buccodentaire, 2011.

B. Uelbelhart, R. Rizzoli, and . Ostéoporose, Rev Med Suisse, vol.8, pp.109-124, 2012.

D. H. Henry, Denosumab versus Zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma, J Clin Oncol, vol.29, pp.1125-1157, 2011.

R. E. Coleman, Clinical features of metastatic bone disease and risk of skeletal morbidity, Clin Cancer Res, pp.12-15, 2006.

R. Coleman, A. Lipton, G. D. Roodman, T. A. Guise, B. F. Boyce et al.,

A. M. , C. P. Croucher, P. I. Gralow, J. R. Hadji, P. Holen et al., Metastasis and bone loss: advancing treatment and prevention

, Cancer Treat Rev, pp.20-615, 2010.

R. E. Coleman, Potential use of bisphosphonates in the prevention of metastases in early-stage breast cancer. Clin Breast Cancer, pp.35-64, 2007.

A. Lipton, G. G. Steger, J. Figueroa, C. Alvarado, P. Solal-celigny et al., Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy

, Clin Cancer Res, pp.14-15, 2008.

J. J. Body, T. Facon, R. E. Coleman, A. Lipton, F. Geurs et al., A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer, Clin Cancer Res, pp.12-15, 2006.

M. Martin, R. Bell, H. Bourgeois, A. Brufsky, I. Diel et al.,

Q. , C. K. Dansey, R. Braun, and A. , Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid, Clin Cancer Res. 2012 Sept, pp.1-18

C. S. Cleeland, J. J. Body, A. Stopeck, R. Von-moos, L. Fallowfield et al., Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid, Cancer, pp.15-119, 2013.

K. Olson and C. Van-poznak, Significance and impact of bisphosphonate-induced acute phase responses, J Oncol Pharm Pract, pp.1-13, 2007.

R. H. Goodday, Preventive Strategies for Patients at Risk of Medication-related Osteonecrosis of the Jaw, Oral Maxillofac Surg Clin North Am, pp.1042-3699, 2015.

, Denosumab, an alternative to bisphosphonates but also associated with osteonecrosis of the jaw-what is the risk?, Br Dent J, pp.219-117, 2015.

X. F. Cao, Y. Zheng, R. C. Zhao, L. Q. Yan, L. Zhao et al., Anti-VEGF Therapy with Bevacizumab-Limited Cardiovascular Toxicity, Asian Pac J Cancer Prev, vol.10769, p.72, 2014.

T. Sugimoto, T. Matsumoto, T. Hosoi, T. Miki, I. Gorai et al., Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial, Osteoporos Int, 2015.

D. Diédhiou, T. Cuny, A. Sarr, N. Diop, S. Klein et al., Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review. An Endocrinol, 2015.

O. Connor and K. M. , Evaluation and Treatment of Osteoporosis, Med Clin North Am, 2016.

R. H. Yang, S. H. Shen, W. Y. Li, and Y. K. Chu, Bisphosphonate-related osteonecrosis of the jaw complicated by Ludwig's angina, J Chin Med Assoc, vol.76, p.9, 2015.

K. Niibe, T. Ouchi, R. Iwasaki, T. Nakagawa, and N. Horie, Osteonecrosis of the jaw in patients with dental prostheses being treated with bisphosphonates or denosumab

, J Prosthodont Res, pp.3-5, 2015.

A. Patrizi, M. Venturi, E. Dika, H. Maibach, P. Tacchetti et al., Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects, Cutan Ocul Toxicol, vol.1, p.6, 2014.

, Breast Care (Basel), pp.320-325, 2015.

M. A. Yassin, A. T. Soliman, D. Sanctis, V. Abdelrahman, M. O. et al., Effects of the anti-receptor activator of nuclear factor kappa B ligand denusomab on beta thalassemia major-induced osteoporosis, Indian J Endocrinol Metab, vol.546, p.51, 2014.

E. Jimi, M. Shin, H. Furuta, Y. Tada, and J. Kusukawa, The RANKL/RANK system as a therapeutic target for bone invasion by oral squamous cell carcinoma (Review), 2013.

, Int J Oncol, vol.803, p.9, 2013.

R. G. Jones and A. Martino, Targeted localized use of therapeutic antibodies: a review of non-systemic, topical and oral applications, Crit Rev Biotechnol, vol.1, p.15, 2015.

F. Elice and F. Rodeghiero, Side effects of anti-angiogenic drugs, Thrombosis Research, vol.129, pp.50-53, 2012.

L. S. Elting, Y. C. Chang, P. Parelkar, C. B. Boers-doets, M. Michelet et al., Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis, Support Care Cancer, vol.3243, p.54, 2013.

S. Takahashi, RANKL antibody for treatment of cancer treatment-induced bone loss (CTIBL), Clin Calcium, vol.1239, p.47, 2011.

A. Boquete-castro, G. Gómez-moreno, J. L. Calvo-guirado, A. Aguilar-salvatierra, and R. A. Delgado-ruiz, Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials, Clin Oral Implants Res, 2015.

X. Wang, K. H. Yang, P. Wanyan, and J. H. Tian, Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trials, Oncol Lett, 2014.

S. Olate, F. Uribe, F. Martinez, A. Almeida, and A. Unibazo, Osteonecrosis of the jaw in patient with denosumab therapy, Int J Clin Exp Med, vol.3707, p.9, 2014.

V. Fusco, C. Porta, G. Saia, C. Paglino, G. Bettini et al., Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature, Clin Genitourin Cancer, 2014.

V. Sibaud, F. Boralevi, E. Vigarios, and J. Fricain,

. Annales-de-dermatologie and . De-vénéréologie, , vol.354, p.63, 2014.

F. Pantano, A. Zoccoli, M. Iuliani, G. Lanzetta, B. Vincenzi et al., New targets, new drugs for metastatic bone pain: a new philosophy, Expert Opin Emerg Drugs, vol.403, p.5, 2011.

E. Dietrich and K. Antoniades, Molecularly targeted drugs for the treatment of cancer: oral complications and pathophysiology, Hippokratia, vol.196, p.9

M. Hello, S. Barbarot, and J. Connault, Manifestations cutanées des thérapies ciblées. La revue de médecine interne, vol.33, pp.273-281, 2012.

E. Dreyer, S. Raymond, and . Faivre, Les thérapies ciblées et leurs indications dans les tumeurs solides. Revue de médecine interne. Revue de médecine interne, vol.30, pp.416-440, 2009.

C. Chevreau, Les effets secondaires des anti-angiogéniques (à l'exception des effets cutanés), Oncologie, vol.285, p.90, 2009.

A. Bozec, J. Thariat, R. Bensadoum, and G. Milano, La chimioradiothérapie des carcinomes épidermoïdes des voies aérodigestives supérieures : point sur les thérapeutiques ciblées, Cancer/Radiothérapie, vol.12, pp.14-24, 2008.

D. W. Williams, C. Lee, T. Kim, H. Yagita, H. Wu et al., Impaired bone resorption and woven bone formation are associated with development of osteonecrosis of the jaw-like lesions by bisphosphonate and anti-receptor activator of NF-?B ligand antibody in mice, Am J Pathol, vol.3084, p.93

S. Takada, Y. Hoshino, H. Ito, Y. Masugi, T. Terauchi et al., Extensive bowel necrosis related to bevacizumab in metastatic rectal cancer patient: a case report and review of literature, Jpn J Clin Oncol, vol.286, p.90, 2015.

G. Misso, M. Porru, A. Stoppacciaro, M. Castellano, D. Cicco et al., Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid, Cancer Biol Ther, vol.1491, p.500, 2012.

F. Joly, K. Bouhier-leporrier, and E. Coquan, Prise en charge des effets secondaires des thérapies ciblées. Potentiel d'action, 2011.

C. Mateus and C. Robert, Effets cutanés des nouvelles molécules utilisées en cancérologie. Revue de médecine interne, vol.30, pp.401-411, 2009.

S. Aissi, B. Mrad, M. Zarraa, S. Bounedjar, A. Laabidi et al., Thérapies anticancéreuses ciblées : vers une nouvelle toxicologie ?, Pathologie Biologie, vol.60, pp.234-242, 2012.

D. Azria and J. Spano, Thérapies ciblées en cancérologie. John libbey eurotext, 2006.

T. Berghmans, Thérapies ciblées : quel traitement pour quel patient ? Revue des, Maladies Respiratoires Actualités, vol.6, pp.459-69, 2014.

S. Vignot and J. Soria, Thérapies moléculaires ciblées, de la biologie au applications cliniques. John libbey eurotext, 2008.

V. Sibaud, Toxicité cutanée induite par les thérapies ciblées anti-angiogéniques

, Oconlogie, vol.11, pp.291-298, 2009.

D. Diédhiou, T. Cuny, A. Sarr, N. Diop, S. Klein et al., Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review. An Endocrinol, 2015.

K. Briot and C. Roux, Ostéoporose post-ménauposique, Rev Med Interne. Mar, pp.195-200, 2016.

D. L. Lacey, E. Timms, H. L. Tan, M. J. Kelley, C. R. Dunstan et al., Osteoprotegerin Ligand is a cytokine that regulates osteoclast differentiation and activation, Cell, vol.93, pp.165-76, 1998.

J. Acquavella, V. Ehrenstein, M. Schiodt, U. Heide-jorgensen, A. Kjellman et al., Toft Sorensen H. Design and methods for a scandinavian pharmacovigilance study of osteonecrosis of the jaw and serious infections among cancer patients treated with antiresorptive agents for the prevention of skeletal-related events, Clin. Epidemiology, issue.8, pp.267-272, 2016.

A. L. Adams, F. Xue, J. Q. Chantra, R. M. Dell, S. M. Ott et al., Sensitivity and specificity of radiographic characteristics in atypical femoral fractures, Osteoporos Int, vol.21, pp.1-5, 2016.